Inventor
FOSTER DONALD
US24 patents
⚠️ This page may combine multiple inventors who share the name “FOSTER DONALD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
20 patentsUS9249415B2Feb 2, 2016
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC24 citations94
US9850488B2Dec 26, 2017
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC11 citations92
US11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US11015201B2May 25, 2021
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10238749B2Mar 26, 2019
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC12 citations84
US9701963B2Jul 11, 2017
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US9376680B2Jun 28, 2016
Serpinc1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US10246713B2Apr 2, 2019
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations83
US11873491B2Jan 16, 2024
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11834661B2Dec 5, 2023
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11419942B2Aug 23, 2022
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11162098B2Nov 2, 2021
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10814007B2Oct 27, 2020
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US11725209B2Aug 15, 2023
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations72
US10829763B2Nov 10, 2020
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US12590305B2Mar 31, 2026
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12584130B2Mar 24, 2026
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11725207B2Aug 15, 2023
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US12503699B2Dec 23, 2025
Compositions and methods for silencing UGT1a1 gene expression
ALNYLAM PHARMACEUTICALS INC0 citations58
US ARMY
2 patentsUS6200356B1Mar 13, 2001
Lithium ion secondary electrochemical cell and a method of preventing the electrochemical dissolution of a copper current collector therein
US ARMY10 citations71
USH1983HAug 7, 2001
Thermal battery and method of making the same having solid complex of SO2 and lithium tetrachloroaluminate as electrolyte
US ARMY5 citations62